Towards Healthcare Research & Consulting

U.S. Intravenous Solutions Companies Strategic Expansion Initiatives

Date : 15 April 2026

Latest Updates of Companies in the U.S. Intravenous Solutions Market

U.S. Intravenous Solutions Market Companies are Baxter International Inc., ICU Medical, Inc., B. Braun Medical Inc., Fresenius Kabi USA, Pfizer Inc.

See the full picture of the U.S. Intravenous Solutions Market without the complexity -Access the dashboard.

Company Headquarters Latest Update
Baxter International Inc. United States In March 2026, Baxter International Inc., a novel leader in infusion therapies and platforms, debuted the IV Verify Line Labeling System, an automated service, at the 2026 American Organization for Nursing Leadership Conference.
ICU Medical, Inc. United States In May 2025, ICU Medical Inc., in partnership with VisionHealth GmbH, announced the launch of MyAcapella, a mobile application intended to support Oscillating Positive Expiratory Pressure (OPEP) therapy for patients with chronic respiratory conditions.
B. Braun Medical Inc. United States In December 2025, B. Braun Medical Inc., a leader in smart infusion therapy and pain management, launched Piperacillin and Tazobactam, one of the most utilized injectable antibiotics in the U.S.
Fresenius Kabi USA United States Fresenius Kabi provides a broad range of generic intravenously administered medications. Significantly severely ill patients in hospitals are treated with these drugs.
Pfizer Inc. United States In September 2025, Pfizer and BioNTech remain deeply committed to making safe and efficient vaccines that supports to protect lives in the U.S. and around the world.  

Recent Developments in the U.S. Intravenous Solutions Market

  • In November 2025, Solventum announced it had entered into a definitive agreement to acquire Acera Surgical, a confidentially held bioscience organization focused on developing and commercializing fully engineered materials for regenerative wound care for $725 million in cash plus up to $125 million in contingent cash payments based on the achievement of certain future milestones.
  • In May 2025, ICU Medical Inc. and Otsuka Pharmaceutical Factory, Inc. (OPF), announced the formation of Otsuka ICU Medical LLC, a novel joint venture with the goal of strengthening the IV solutions supply chain
  • In April 2025, Organon, a worldwide healthcare organization with a deep expertise in biosimilars, announced that it had acquired from Biogen Inc. regulatory and commercial rights in the U.S. for TOFIDENCE, a biosimilar to ACTEMRA, for intravenous infusion.
  • In March 2025, AstraZeneca entered into a definitive agreement to acquire EsoBiotec, a biotechnology company pioneering in vivo cell therapies that have demonstrated promising initial clinical activity. The EsoBiotec Engineered NanoBody Lentiviral platform authorizes the immune system.

Supply Chain Analysis

R&D:

  • Research and development (R&D) in intravenous solutions includes a rigorous process focused on design stability, sterilization validation, container compatibility, and government compliance to ensure efficacy and safety.
  • Key Players: Pfizer Inc. and Grifols, S.A. 

Manufacturing Processes:

  • The manufacturing processes for intravenous solutions involve water purification, mixing ingredients, microfiltration, sterile container forming and filling, terminal sterilization, and advanced quality control testing.
  • Key Players: Baxter International Inc. and ICU Medical, Inc.

Patient Services:

  • Patient services in intravenous (IV) solution therapy include the administration of fluids, electrolytes, medications, or nutrients directly into the bloodstream to manage dehydration, shock, or metabolic inequities
  • Key Players: B. Braun Medical Inc. and Fresenius Kabi USA

Market Trends

The U.S. intravenous solutions market size was estimated at USD 5.82 billion in 2025 and is predicted to increase from USD 6.19 billion in 2026 to approximately USD 10.82 billion by 2035, expanding at a CAGR of 6.4% from 2026 to 2035. The U.S. intravenous solutions market is growing because of the rising prevalence of chronic and acute health diseases that need fluid therapy, boosted by technological development and increasing healthcare infrastructure.

U.S. Intravenous Solutions Market Size is USD 6.19 Billion in 2026.